Autolus: Good Product, But Tricky Market Dynamics (Rating Downgrade)
Source: SeekingAlpha
2025-11-01 08:25:20 ET
Investment Overview
I last covered the United Kingdom-headquartered, commercial-stage biotech company Autolus ( AUTL ) for Seeking Alpha in June, assigning the stock a Buy rating . I also gave the stock a Buy rating in a note published in September last year , and in February 2024 , and another back in August 2021 ....
Read the full article on Seeking Alpha
For further details see:
Autolus: Good Product, But Tricky Market Dynamics (Rating Downgrade)
Autolus Therapeutics plc
NASDAQ: AUTL
AUTL Trading
18.73% G/L:
$1.87 Last:
2,635,914 Volume:
$1.62 Open:
AUTL Latest News
May 14, 2026 07:00:00 am
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesMay 05, 2026 07:00:00 am
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026April 29, 2026 04:05:00 pm
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionAUTL Stock Data
$387,238,481
109,839,996
N/A
49
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
